OMEROS CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
OMEROS CORP (OMER) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $10.32 per share for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-01.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2019-03-01
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2015-09-30 was $8.09, a 20.53% decline year-over-year.
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2015-06-30 was $12.63, a 54.02% increase year-over-year.
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2015-03-31 was $13.49.
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2014-09-30 was $10.18, a 50.37% increase year-over-year.
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2018 was $10.32, a 19.17% increase from fiscal 2017.
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2017 was $8.66, a 25.69% increase from fiscal 2016.
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2016 was $6.89, a 39.08% decline from fiscal 2015.
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2015 was $11.31, a 53.04% increase from fiscal 2014.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2018-12-31 | $10.32 10-K · filed 2019-03-01 | |||
| 2017-12-31 | $8.66 10-K · filed 2019-03-01 | |||
| 2016-12-31 | $6.89 10-K · filed 2019-03-01 | |||
| 2015-12-31 | $11.31 10-K · filed 2018-03-01 | |||
| 2015-09-30 | $8.09 10-Q · filed 2015-11-09 | $12.08 10-Q · filed 2015-11-09 | ||
| 2015-06-30 | $12.63 10-Q · filed 2015-08-10 | $12.97 10-Q · filed 2015-08-10 | ||
| 2015-03-31 | $13.49 10-Q · filed 2015-05-11 | |||
| 2014-12-31 | $7.39 10-K · filed 2017-03-16 | |||
| 2014-09-30 | $10.18 10-Q · filed 2015-11-09 | $8.39 10-Q · filed 2015-11-09 | ||
| 2014-06-30 | $8.20 10-Q · filed 2015-08-10 | $8.20 10-Q · filed 2015-08-10 | ||
| 2013-12-31 | $6.87 10-K · filed 2016-03-15 | |||
| 2013-09-30 | $6.77 10-Q · filed 2014-11-10 | $6.73 10-Q · filed 2014-11-10 | ||
| 2013-06-30 | $3.57 10-Q · filed 2014-08-11 | $3.57 10-Q · filed 2014-08-11 | ||
| 2012-12-31 | $7.35 10-K · filed 2015-03-16 | |||
| 2012-09-30 | $6.63 10-Q · filed 2013-11-07 | $3.32 10-Q · filed 2013-11-07 | ||
| 2012-06-30 | $7.09 10-Q · filed 2013-08-09 | $3.28 10-Q · filed 2013-08-09 | ||
| 2012-03-31 | $3.21 10-Q · filed 2013-05-09 | |||
| 2011-12-31 | $3.31 10-K · filed 2014-03-13 | |||
| 2011-09-30 | $0.00 10-Q · filed 2012-11-09 | $3.65 10-Q · filed 2012-11-09 | ||
| 2011-06-30 | $3.07 10-Q · filed 2012-08-07 | $3.65 10-Q · filed 2012-08-07 | ||
| 2010-12-31 | $4.34 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |